EyeBio Announces First Patients Dosed in Phase 1b/2 Trial of Restoret™ in Neovascular Age Related Macular Degeneration and Diabetic Macular Edema
LONDON & NEW YORK--(BUSINESS WIRE)--Jun 14, 2023--
Source: eagletribune.com
📰 Jonathan Prenner News
Jonathan Prenner News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jonathan Prenner. Real-time updates on events, politics, business and more.
Eyebiotech Limited: EyeBio Announces First Asset in Innovative Pipeline of Retinal Disease Treatments and Appoints Industry Leaders to Executive Team
Additions to EyeBio's leadership team include world-class disruptors with deep experience addressing urgent unmet needs in treatment of eye diseases - EyeBio co-founder Anthony P. Adamis, M.D., appointed
Source: finanznachrichten.de
Eyebiotech Limited: EyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies
Leaders in ophthalmology drug development launch new global company to build and advance diversified portfolio of ocular therapies Eyebiotech Limited (EyeBio), a privately held ophthalmology biotechnology
Source: finanznachrichten.de
EyeBiotech Raises $65M in Series A Funding
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
The Fifth Annual Retina Fellow Summit
The Fifth Annual Retina Fellow Summit This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. 2.00 CME Activity Expiration Date: 12/31/2021 Activity Overview This activity features highlights captured from the Fifth Annual Retina Fellow Summit held in November 2020. The Summit included an expert faculty panel and an audience of retina fellows engaging in discussions on current clinical data, clinical cases, and practice transiti...
Johns Hopkins University United States Robert Wood Johnson Medical School New Jersey New Brunswick Palo Alto
Source: healio.com